PDF(Sci-hub)
Abstract：
To evaluate the treatment success, possible side effects, and safety of radiofrequency ablation with the Sonata System.
An electronic literature search in the PubMed and Medline databases was carried out from inception to August 2020.
The review was performed in accordance with the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analysis. Keywords such as \"Sonata,\" \"transcervical ablation,\" and \"uterine myoma\" were used to identify all relevant articles independently by both authors. Full-text articles in English that reported at least 1 of the following outcomes were included in the study: reduction in perfused/total myoma volume, effect of treatment on bleeding intensity and myoma-related symptoms, number of surgical reinterventions, adverse events, return to activities of daily life, effects on surrounding tissue, and safety during pregnancy.
10 studies matching the inclusion criteria were identified and used for further analysis. A reduction in total and perfused myoma volume of 63.2% and 64.5% was achieved. One of the studies showed a 53.8 ± 50.5% (n = 48) reduction in Menstrual Pictogram Score, and another study showed a 51.1 ± 40.9% (n = 142) reduction in Pictorial Blood Loss Assessment Chart at 12 months. 87.2% (n = 190) of the patients reported a clinically meaningful reduction in menstrual blood loss after 12 months. While Symptom Severity Scores dropped by 28.8 ± 19.3, 23.3 ± 23.7, and 23.7 ± 19.4 points at 3, 6, and 12 months, respectively, Health-Related Quality of Life Scores increased to 77.5 ± 22.0, 82.8 ± 19.0, and 83.3 ± 20.5 points. One study had an 8% reintervention rate after 12 months, and another study showed a 0.7% and 5.2% rate after 12 and 24 months. After an average of 64 months after ablation, the reintervention rate was 11.8%. Time to return to activities of daily life was 2.9 ± 2.5 days. No related complications during pregnancy and delivery were reported.
Radiofrequency ablation with the Sonata System represents a minimally invasive, organ-preserving treatment option in patients with symptomatic uterine myomas, associated with clinically meaningful improvement of myoma-related symptoms.
An electronic literature search in the PubMed and Medline databases was carried out from inception to August 2020.
The review was performed in accordance with the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analysis. Keywords such as \"Sonata,\" \"transcervical ablation,\" and \"uterine myoma\" were used to identify all relevant articles independently by both authors. Full-text articles in English that reported at least 1 of the following outcomes were included in the study: reduction in perfused/total myoma volume, effect of treatment on bleeding intensity and myoma-related symptoms, number of surgical reinterventions, adverse events, return to activities of daily life, effects on surrounding tissue, and safety during pregnancy.
10 studies matching the inclusion criteria were identified and used for further analysis. A reduction in total and perfused myoma volume of 63.2% and 64.5% was achieved. One of the studies showed a 53.8 ± 50.5% (n = 48) reduction in Menstrual Pictogram Score, and another study showed a 51.1 ± 40.9% (n = 142) reduction in Pictorial Blood Loss Assessment Chart at 12 months. 87.2% (n = 190) of the patients reported a clinically meaningful reduction in menstrual blood loss after 12 months. While Symptom Severity Scores dropped by 28.8 ± 19.3, 23.3 ± 23.7, and 23.7 ± 19.4 points at 3, 6, and 12 months, respectively, Health-Related Quality of Life Scores increased to 77.5 ± 22.0, 82.8 ± 19.0, and 83.3 ± 20.5 points. One study had an 8% reintervention rate after 12 months, and another study showed a 0.7% and 5.2% rate after 12 and 24 months. After an average of 64 months after ablation, the reintervention rate was 11.8%. Time to return to activities of daily life was 2.9 ± 2.5 days. No related complications during pregnancy and delivery were reported.
Radiofrequency ablation with the Sonata System represents a minimally invasive, organ-preserving treatment option in patients with symptomatic uterine myomas, associated with clinically meaningful improvement of myoma-related symptoms.
摘要：
为了评估治疗的成功，可能的副作用,索纳塔系统射频消融的安全性。
从成立到2020年8月，在PubMed和Medline数据库中进行了电子文献检索。
根据系统评价和荟萃分析的首选报告项目指南进行审查。关键词如\"奏鸣曲,\"\"经宫颈消融,两位作者分别使用“”和“子宫肌瘤”来鉴定所有相关文章。研究中纳入了以下至少一项结果的英文全文文章：灌注/总肌瘤体积减少，治疗对出血强度和肌瘤相关症状的影响，手术再干预的数量，不良事件,回到日常生活的活动，对周围组织的影响，怀孕期间的安全。
确定了符合纳入标准的10项研究，并用于进一步分析。总的和灌注的肌瘤体积减少了63.2%和64.5%。其中一项研究显示，月经象形图评分降低了53.8±50.5%(n=48)，另一项研究显示，在12个月时，图形失血评估图表减少了51.1±40.9%（n=142）。87.2％（n=190）的患者报告12个月后月经失血有临床意义的减少。症状严重程度评分在3、6和12个月时分别下降了28.8±19.3、23.3±23.7和23.7±19.4分，分别,与健康相关的生活质量分数增加到77.5±22.0、82.8±19.0和83.3±20.5分。一项研究在12个月后有8%的再干预率，另一项研究显示，12个月和24个月后的比率分别为0.7%和5.2%。消融后平均64个月，再干预率为11.8%.恢复日常生活活动的时间为2.9±2.5天。未报告妊娠和分娩期间的相关并发症。
使用奏鸣曲系统进行射频消融代表了一种微创，有症状的子宫肌瘤患者的器官保留治疗选择，与有临床意义的肌瘤相关症状改善相关。
从成立到2020年8月，在PubMed和Medline数据库中进行了电子文献检索。
根据系统评价和荟萃分析的首选报告项目指南进行审查。关键词如\"奏鸣曲,\"\"经宫颈消融,两位作者分别使用“”和“子宫肌瘤”来鉴定所有相关文章。研究中纳入了以下至少一项结果的英文全文文章：灌注/总肌瘤体积减少，治疗对出血强度和肌瘤相关症状的影响，手术再干预的数量，不良事件,回到日常生活的活动，对周围组织的影响，怀孕期间的安全。
确定了符合纳入标准的10项研究，并用于进一步分析。总的和灌注的肌瘤体积减少了63.2%和64.5%。其中一项研究显示，月经象形图评分降低了53.8±50.5%(n=48)，另一项研究显示，在12个月时，图形失血评估图表减少了51.1±40.9%（n=142）。87.2％（n=190）的患者报告12个月后月经失血有临床意义的减少。症状严重程度评分在3、6和12个月时分别下降了28.8±19.3、23.3±23.7和23.7±19.4分，分别,与健康相关的生活质量分数增加到77.5±22.0、82.8±19.0和83.3±20.5分。一项研究在12个月后有8%的再干预率，另一项研究显示，12个月和24个月后的比率分别为0.7%和5.2%。消融后平均64个月，再干预率为11.8%.恢复日常生活活动的时间为2.9±2.5天。未报告妊娠和分娩期间的相关并发症。
使用奏鸣曲系统进行射频消融代表了一种微创，有症状的子宫肌瘤患者的器官保留治疗选择，与有临床意义的肌瘤相关症状改善相关。
